Forest Will Delay Nebivolol NDA For CHF Pending FDA Review Of Hypertension Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is currently wrapping up pharmacokinetic studies needed to respond to an “approvable” letter for hypertension NDA.
You may also be interested in...
Forest And Mylan Confident Nebivolol Will Reach Market In Early 2008
FDA “approvable” letter seen by firms as minor hurdle for previously delayed hypertension drug.
Forest And Mylan Confident Nebivolol Will Reach Market In Early 2008
FDA “approvable” letter seen by firms as minor hurdle for previously delayed hypertension drug.
Forest/Mylan Respond To FDA “Approvable” Letter On Nebivolol
Forest estimates review of the novel hypertension drug could take six months.